Pharma Companies to Unveil Clinical Trial Data at 2024 ASCO Annual Meeting

Pharma Companies to Unveil Clinical Trial Data at 2024 ASCO Annual Meeting

Emilia Santiago
3 min read

Major Pharmaceutical Companies to Present Clinical Data at 2024 ASCO Annual Meeting

At the 2024 ASCO Annual Meeting, multiple pharmaceutical companies are set to showcase significant clinical data from ongoing trials. Merck & Co will unveil the Phase III study results for its antibody-drug conjugate therapy, Sac-TMT, designed for the treatment of triple-negative breast cancer. Notably, Pfizer, following its acquisition of Seagen, will present data on Adcetris in relapsed/refractory diffuse large B-cell lymphoma, with plans for a regulatory submission. Additionally, Astellas Pharma will present pivotal data, including Phase III EV-302 trial data on Padcev in urothelial carcinoma and overall survival data from the SPOTLIGHT study on Vyloy for gastric or GEJ adenocarcinoma.

Key Takeaways

  • Merck & Co, Pfizer, Astellas, and other pharmaceutical giants will unveil pivotal clinical data at the 2024 ASCO Annual Meeting.
  • Merck's Phase III study results on Sac-TMT for treating triple-negative breast cancer will be among the highlights of the event.
  • Pfizer's presentation of Adcetris + lenalidomide and rituximab for relapsed/refractory DLBCL, with OS improvement, is a significant development.
  • Astellas will present 16 notable abstracts, including the combination therapy of Padcev with Keytruda for urothelial carcinoma and Vyloy's OS data for gastric/GEJ adenocarcinoma, which was previously rejected by the FDA but has now been approved in Japan.


The disclosure of clinical data by Merck, Pfizer, and Astellas at the 2024 ASCO Annual Meeting carries substantial implications for the landscape of cancer treatment. Merck's Phase III results for Sac-TMT in triple-negative breast cancer may potentially broaden treatment options, while Pfizer's venture into Adcetris data could reinforce its position in the oncology sector following the acquisition of Seagen. Moreover, Astellas' data may bring about advancements in urothelial carcinoma and gastric/GEJ adenocarcinoma therapies. Nevertheless, probable hindrances in terms of regulatory processes and market competition cannot be overlooked. Investors in these corporations should closely track forthcoming developments, as these revelations may have a direct impact on their financial performance. Additionally, the medical community and patients should anticipate nuanced updates in treatment guidelines and options.

Did You Know?

  • ASCO Annual Meeting: A critical conference for oncologists and cancer professionals to discuss and present the latest research and developments in cancer treatment.
  • Antibody-drug conjugate (ADC) therapy: A type of cancer treatment that merges an antibody with a cytotoxic drug, delivering the drug directly to cancer cells while minimizing harm to healthy cells.
  • Sac-TMT: An ADC therapy developed by Merck & Co specifically designed for the treatment of triple-negative breast cancer.
  • Triple-negative breast cancer: A challenging and aggressive type of breast cancer that lacks the expression of certain receptors, making it harder to treat.
  • Adcetris: An ADC therapy licensed to Takeda Oncology, developed by Seagen for the treatment of cancer.
  • Diffuse large B-cell lymphoma (DLBCL): A prevalent type of non-Hodgkin lymphoma in adults, known for its aggressive nature.
  • Relapsed/refractory DLBCL: DLBCL that has either recurred after initial treatment or has failed to respond to it.
  • Pfizer-Seagen acquisition: Pfizer's acquisition of Seagen in 2023 for $43 billion, augmenting its oncology portfolio.
  • Padcev: An ADC therapy developed by Astellas Pharma for treating urothelial carcinoma, a type of bladder cancer.
  • Keytruda: An immunotherapy drug developed by Merck & Co for the treatment of various cancer types.
  • Urothelial carcinoma: The most common type of bladder cancer in the United States.
  • Vyloy: An ADC therapy developed by Astellas Pharma for the treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma.
  • Gastric or GEJ adenocarcinoma: A common and aggressive stomach cancer with a poor prognosis.
  • FDA approval: Astellas Pharma's Vyloy, initially rejected by the FDA, has received approval for use in Japan.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings